Arrowhead Pharmaceuticals announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-MMP7, the company’s investigational RNA interference RNAi therapeutic designed to reduce the expression of matrix metalloproteinase 7 as a potential treatment for idiopathic pulmonary fibrosis . "MMP7 is thought to play multiple roles in IPF pathogenesis, including promoting inflammation and aberrant epithelial repair and fibrosis," said James Hamilton, M.D., MBA, chief of discovery and translational medicine at Arrowhead. "ARO-MMP7 offers a novel approach to potentially address the significant unmet medical need that exists for patients with IPF, who experience progressive decline of lung function, despite currently available therapies."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ARWR:
- Cantor Fitzgerald biotech analyst to hold analyst/industry conference call
- Arrowhead price target lowered to $60 from $82 at Chardan
- Arrowhead price target lowered to $55 from $64 at Piper Sandler
- Takeda Pharmaceutical, Arrowhead announce topline results from SEQUOIA study
- Arrowhead announces $25M milestone payment from Amgen